ロード中...
Risperidone versus other atypical antipsychotics for schizophrenia
BACKGROUND: In many countries of the industrialised world second-generation (“atypical”) antipsychotics (SGAs) have become the first line drug treatment for people with schizophrenia. The question as to whether and if so how much the effects of the various SGAs differ is a matter of debate. In this...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4167865/ https://ncbi.nlm.nih.gov/pubmed/21249678 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD006626.pub2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|